Phase IV, Double Blind, Multi-Center, Randomized, Two-Arm Crossover Study to Compare 0.1 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem and 0.05 mmol/kg of MultiHance With 0.1 mmol/kg of Dotarem in MRI of the Brain
Phase of Trial: Phase IV
Latest Information Update: 12 Jan 2017
At a glance
- Drugs Gadobenic acid (Primary) ; Gadoterate-meglumine
- Indications Brain disorders
- Focus Diagnostic use
- Acronyms BENEFIT
- Sponsors Bracco Diagnostics
- 14 Nov 2016 Status changed from active, no longer recruiting to completed.
- 26 Feb 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 05 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.